Important scientific questions remain unanswered in the effort to develop a safe and effective Ebola vaccine, according to members of an international Ebola research consortium.
A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists.
A new study is shedding light on the role of specific proteins that trigger a mechanism allowing Ebola virus to enter cells to establish replication.
Researechers compared immune responses induced by Ebola virus glycoprotein subunit vaccines via intradermal immunization with microneedle (MN) patches and the conventional intramuscular injection in mice.
Scientists have discovered a set of powerful, broadly neutralizing antibodies in the blood of Ebola virus disease survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by Zaire ebolavirus, Bundibugyo ebolavirus and Sudan ebolavirus, the three species known to cause fatal human illness.
In August 2015, a nonhuman primate facility south of Manila, the Philippines, noted unusual deaths of six cynomolgus monkeys (Macaca fascicularis), characterized by generalized rashes, inappetence, or sudden death.
The central African country has dealt with more outbreaks of Ebola disease than any other nation, yet exactly why the DRC is hit so often remains an unanswered question.
A new collaborative study has identified and studied Ebola antibodies that could be used to design universal therapeutics that are effective against many different Ebola species.
There are challenges that must be overcome to ensure adequate preparedness for future Ebola outbreaks, including completing the remaining advanced development activities necessary for regulatory approval and subsequent stockpiling of medical countermeasures for use during a public health emergency.